Business Standard

Cadila Healthcare at the forefront, looks at biologic drug to treat Covid

Company is already working on developing 2 vaccine candidates, diagnostic kits and also making HCQ

pharmaceutical, pharma, testing, research, doctors, health, drugs, medicine, labaratory
Premium

Cadila Healthcare has been commercially making Pegylated Interferon alpha 2b under the brand name PegiHep

Sohini Das Mumbai
Ahmedabad-based pharmaceutical major Cadila Healthcare has emerged at the forefront of India’s battle to fight the coronavirus disease (Covid-19). After announcing research on two vaccine candidates, work on developing rapid diagnostic kits and ramping up production of hydroxychloroquine (HCQ), the company is now exploring the use of a biologic drug Interferon alfa-2b to treat Covid-19.
 
Recent studies have shown evidence of a direct antiviral effect of Interferon alfa-2b against the new coronavirus. Cadila Healthcare (Zydus Cadila) has been commercially making Pegylated Interferon alfa-2b under the brand name Pegihep since 2011 for the treatment of Hepatitis B and C, with 150,000

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Apr 20 2020 | 12:25 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com